Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

775.45 -19.67 (-2.47%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Which Stock Will Dominate the Weight Management Market Through 2030?
Via The Motley Fool
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations. 
Via Benzinga
GLP-1 Showdown In India: Eli Lilly’s Mounjaro Pen Approved Just Days After Novo’s Wegovy Launch
Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry. 
Via Stocktwits
Topics Intellectual Property
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Why This Weight Loss Drug Company's Stock Surged Today
Via The Motley Fool
3 Growth Stocks I'm Loading Up On
Via The Motley Fool
Topics Artificial Intelligence Government
5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the... 
Via StockStory
Topics Earnings World Trade
Why Shares in Novo Nordisk Lost Weight Today
Via The Motley Fool
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years. 
Via Benzinga
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss. 
Via Investor's Business Daily
What's Going On With Viking Therapeutics Stock On Wednesday?
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks. 
Via Benzinga
Which S&P500 stocks are moving on Wednesday?
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
Tesla's Robotaxi Rollout
Via The Motley Fool
Topics Stocks
7 Space Stocks I'd Buy Without Hesitation
Via The Motley Fool
Topics Artificial Intelligence Economy
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
Via The Motley Fool
Topics Government World Trade
Eli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s Sold
Bimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more data is needed. 
Via Stocktwits
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio. 
Via Benzinga
Hims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically... 
Via Stocktwits
Amgen Expands Development Plans For Highly Anticipated Obesity Drug
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies. 
Via Investor's Business Daily
Why Novo Nordisk Stock Is Sinking Today
Via The Motley Fool
Topics Stocks Supply Chain
IWF Is a Great Choice for Most, But I Like VUG ETF Better
Via The Motley Fool
Topics ETFs
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals. 
Via Benzinga
Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns
Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects. 
Via Benzinga
Watch Out, Novo Nordisk & Eli Lilly: Chinese Biotech Steps Into the Ring To Take On Global Weight-Loss Leaders
Sciwind Biosciences is expanding its global footprint with licensing deals and early talks for overseas development, as it eyes a double-digit market share in China's fast-growing obesity drug sector. 
Via Stocktwits
Eli Lilly Hits Dual Wins: Orforglipron, Efsitora Meet Phase 3 Goals For Blood Sugar, Weight Loss And Diabetes Care
Efsitora matched or exceeded A1C reductions seen with daily basal insulin across three trials, while orforglipron demonstrated benefits for blood sugar control and weight loss at higher doses. 
Via Stocktwits
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Via The Motley Fool
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs. 
Via Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
3 'Underdog Stocks' For The Rest Of 2025
Via Benzinga
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.